AKL1 is a novel, patented, botanically derived pharmaceutical product developed as a treatment for Asthma.
 
Asthma, a chronic disease of the airways, is characterised by recurrent airway obstruction. The cause of this obstruction remains unknown. Despite several carefully worded statements during the past decade we do not have a definition of asthma that is applicable to all cases. This difficulty reflects not only the lack of a single biological marker or clinical test for asthma but also the variable expression of symptoms, multiple etiological factors, heterogeneous responses to treatment, and differing outcomes.
 
Is Asthma more than just a Bronchial Disease? The whole mucosal immune system appears to be involved in bronchial asthma. Although devoid of gastrointestinal symptoms, asthmatics and asymptomatic allergic individuals have shown duodenal pathologic abnormalities mimicking those observed in the bronchial mucosa. The reasons for the preferential involvement of the airways in asthma are not known but may be related to the route and dose of allergen exposure or early injury to the airways.
 
The mucosal immune system is characterized by the fact that activated T lymphocytes are able to migrate from one mucosal site to another one. Asthmatic patients exhibited an “airway-like” inflammation of various mucosal sites (such as gut mucosa or minor salivary glands), suggesting that the whole mucosal system is involved as a cause or as a consequence in asthma. (Wallaert B et al.. Allergy and Clinical Immunology International, Vo12, No.4, 2000 9
 
Assessing asthma control has led to the development of the Asthma Control Test (ACT) (Nathan, 2004). The ACT is a brief, five-item, easily administered survey that can screen patients with poorly controlled asthma. Using a five-point(1=not controlled at all to 5=completely controlled), both patient and provider can assess the patient’s level of control for the prior four weeks on five items: shortness of breath, patient rating of control, use of rescue medication, activity limitations, and night-time awakenings.
 
In developing the ACT, investigators found a stronger correlation between the specialists’s rating of control and ACT scores than between the specialist’s rating of control and FEV1 measurements suggesting that it may not be advisable to assess asthma control solely on the basis of airway function. The investigators suggested combining the ACT score and forced expiratory volume in 1 second (FEV1) value to obtain the most accurate measurement of control (Schatz, 2004).
 
Any resolution of symptoms in the asthma syndrome is a major advance. AKL 1 has been shown to reduce asthma symptoms. Please contact us for further information.